Qprotyn achieves viscosity of 14 cP for 250mg/mL of Bevacizumab using its HILOPRO® technology.
Upgrading Bevacizumab from IV to subcutaneous (SubQ) administration may now be possible with Qprotyn's HILOPRO technology Innovator Bevacizumab was first sold under the brand name Avastin(R) by Genentech - a member of the Roche Group. First approved in the United States in 2004 and in the European Union in 2005, Bevacizumab is now used to treat different types of cancers and age-related macular degeneration (AMD) particularly for the choroidal neovascular membrane in AMD. To